Elevai Labs' Elevai Biosciences Engages Leading Contract Research Organization To Support Regulatory Planning Efforts And Pre-IND Meeting With The FDA For EL-22 For The Treatment Of Obesity
Portfolio Pulse from Benzinga Newsdesk
Elevai Biosciences, a subsidiary of Elevai Labs (NASDAQ:ELAB), is preparing for an IND application to the FDA for EL-22, a novel treatment for obesity that preserves muscle mass. They have partnered with KCRN Research to support regulatory planning and aim to submit the application in 2025.
October 22, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevai Biosciences, a subsidiary of Elevai Labs, is advancing its novel obesity treatment, EL-22, by engaging KCRN Research for regulatory planning. The IND application is targeted for 2025, potentially positioning ELAB as a key player in obesity treatment.
The partnership with KCRN Research and the planned IND submission for EL-22 could position Elevai Labs as a significant player in the obesity treatment market. This news is likely to positively impact ELAB's stock as it shows progress in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90